Author:
MacVane Shawn H.,Kuti Joseph L.,Nicolau David P.
Abstract
ABSTRACTAdvanced-generation cephalosporins are frequently used for empirical coverage of ventilator-associated pneumonia (VAP) due to their activity against a broad spectrum of Gram-positive and Gram-negative aerobic bacteria, includingPseudomonas aeruginosaandEnterobacteriaceae. Providing optimal antibiotic exposure is essential to achieving successful response in patients with VAP. We evaluated exposures of two antipseudomonal cephalosporins, ceftazidime and cefepime, in patients with VAP due to Gram-negative bacilli to identify the pharmacodynamic parameter predictive of microbiological success. Population pharmacokinetic models were used to estimate individual free drug exposures. Pharmacodynamic indices were determined for each patient using the baseline Gram-negative bacilli with the highest drug MIC. Classification and regression tree analysis was utilized to partition exposure breakpoints, and multivariate logistic regression was conducted to identify predictors of microbiological success. A total of 73 patients (18 receiving ceftazidime therapy and 55 receiving cefepime therapy) were included. MICs ranged widely from 0.047 to 96 μg/ml. The microbiological success rate was 58.9%. Predictive breakpoints were identified for all pharmacodynamic parameters, including a serumfT > MIC greater than 53% (P= 0.02). When controlling for APACHE II (odds ratio [OR], 1.01; 95% confidence interval, 0.93 to 1.09;P= 0.85) and combination therapy (OR, 0.74; 95% confidence interval, 0.25 to 2.19;P= 0.59), achieving a greater than 53%fT > MIC remained a significant predictor of success (OR, 10.3; 95% confidence interval, 1.1 to 92.3;P= 0.04). In patients with VAP due to Gram-negative bacilli, serum exposure of greater than 53%fT > MIC was found to be a significant predictor of favorable microbiological response for antipseudomonal cephalosporins. These data are useful when determining dosing regimens for cephalosporin agents under development for pneumonia.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference39 articles.
1. Ventilator-associated pneumonia;Chastre;Am. J. Respir. Crit. Care Med.,2002
2. Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy;Bassetti;Expert Rev. Anti Infect. Ther.,2012
3. Ceftazidime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use;Richards;Drugs,1985
4. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime;Masuyoshi;Drugs Exp. Clin. Res.,1989
5. The use of cefepime (BMY 28142) to treat respiratory infections;Clynes;Diagn. Microbiol. Infect. Dis.,1989
Cited by
63 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献